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a  b  s  t  r  a  c  t
Nowadays,  stem  cells  have  been  introduced  as  an  appropriate  source  of regenerative  medicine  for
treatment  of  type I diabetes.  Human  umbilical  cord  matrix-derived  mesenchymal  cells  (hUCMC)  have
successfully  been  differentiated  into  insulin  producing  cells.  The  isolated  hUCM  cells  were  characterized
by  the  expression  of  stem  cell surface  markers  and  by  differentiation  into  adipocytes  and  osteocytes.
The  hUCMCs  were  cultured  with  different  concentrations  of  neural  conditional  medium  (NCM)  and  were
induced  to  differentiate  into  insulin  producing  cells (IPCs).  As  60%  NCM  concentration  resulted  in  higher
nestin  and  PDX1  expression,  the  cells  were  ﬁrst exposed  to  60%  NCM  and were  then  induced  for  IPCs
differentiation.  PDX1  and  insulin  gene  expression  was  evaluated  in  the  treated  cells.  Also,  the  secretion
capacity  of  the IPCs  was assessed  by  glucose  challenge  test.  IPCs  were  transferred  under  the  rat  kid-
ney  capsule.  Blood  glucose  level,  weight  gain  and  immunohistochemistry  assessments  were  done  in the
treated  animals.  hUCMC  expressed  mesenchymal  cell  surface  markers  and  successfully  differentiated
into  adipocytes  and  osteocytes.  Higher  NCM  concentration  resulted  in  higher  PDX1  and nestin  expres-
sion.  The  IPCs  expressed  insulin  and  PDX1.  IPCs  were  detectable  under  the kidney  capsule  2  months
after  injection.  IPCs  transplantation  resulted  in a sharp  decline  of  blood  sugar  level  and less  weight  loss.
Differentiated  hUCM  cells  could  alleviate  the insulin  deprivation  in the rat  model  of  type I diabetes.  In
addition,  higher  NCM  concentration  leads  to more  differentiation  into  IPCs  and  more  nestin  and  PDX1
expression.  Kidney  capsule  can  serve  as  a suitable  nominee  for IPCs  transplantation.
© 2015  Elsevier  Ltd. All  rights  reserved.. Introduction
The autoimmune destruction of insulin producing cells (IPCs)
f pancreas eventuates in the ablation of pancreatic  cells. The
utcome is insufﬁcient insulin secretion and type I diabetes; a com-
lex metabolic disorder which is increasing worldwide (Wild et al.,
004). Insulin is administered for the control of hyperglycemia but
t cannot prevent long term complications such as vascular disor-
ers, kidney failure, neuropathy, cardiovascular disease, blindness
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040-8166/© 2015 Elsevier Ltd. All rights reserved.and stroke (Froud et al., 2005). A combination of treatments includ-
ing drug administration and islet transplantation are applied to
minimize the risk of further complications (Drucker et al., 2010).
A new form of treatment known as cell transplantation which is
based on pancreatic islet cells injection, has recently been inno-
vated. However, the number of accessible donated pancreatic islets
is very limited (Hussain and Theise, 2004). To unravel this problem,
some studies have focused on ﬁnding a suitable cell sources, an
appropriate differentiation protocol and on the route of cell trans-
plantation with minimal complications (Soria et al., 2008). Till now,
many types of stem cells have been introduced for the treatment
of diabetes, which are classiﬁed into embryonic stem cells (ESC),
adult stem cells and extra embryonic or infant stem cells which are
isolated from cord blood and placenta (Van, 2011). Umbilical cord
matrix-derived cells (Wharton’s jelly cells) have the properties of
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esenchymal cells (Anzalone et al., 2011). These multipotent cells
Fong et al., 2007) have an embryonic origin and they do not face any
thical precautions and teratoma formation following transplanta-
ion. Also transplantation of differentiated hUCMCs, has resulted in
o immuno rejection complications (Weiss et al., 2006, 2008).
Although stem cell therapy in diabetes is still in its infancy
eriod, by considering the hUCM cells accessibility and unique
mmunological characteristics, establishing an appropriate pro-
ocol for in vitro differentiation of these cells into IPCs and
ransplantation of induced cells into a suitable animal model would
e a long step toward the type I diabetes treatment.
In the present study we assessed the effect of different concen-
rations of neural conditional medium (NCM) on nestin and PDX1
xpression followed by a three steps protocol to induce hUCMCs to
PCs. The insulin and C-peptide secretion levels were evaluated by
lucose challenge test. Also the insulin and PDX1 expressions were
etected by semi quantitative RT-PCR. In the next step, we trans-
lanted the induced cells under the kidney capsule of the rat models
f type I diabetes and the blood glucose level and body weight were
ssessed in the treated animals within 8 weeks.
. Materials and methods
All the materials were purchased from Sigma Company
Sigma–Aldrich, MO,  USA) unless those otherwise stated. The
nstitutional ethical review board (approval number 69-1780) of
erman University of Medical Sciences, Kerman, Iran, issued ethical
pproval.
.1. Isolation of human umbilical cord Wharton jelly
esenchymal cells
We  used a previously reported protocol for harvesting hUCM
ells (Salehinejad et al., 2012) with few modiﬁcations. Brieﬂy, the
mbilical cords (UC) were obtained from cesarean section of full-
erm pregnancy with no complications, after a written consent from
he mothers. The UCs (Fig. 1A) were washed with PBS, the amnion
nd vessels were removed, the matrix was cut into small pieces
nd transferred into culture dishes (Becton Dickinson & Company
ranklin Lakes) (Fig. 1B) with DMEM,  20% FBS (Gibco), 200 IU/ml
enicillin, streptomycin and 2 g/ml amphotericin B. The culture
ishes were incubated at 37 ◦C with 5% CO2 in the humidiﬁed air.
he culture media was refreshed every 72 h. After the hUCM cells
ppeared at the margin of fragments, the matrix fragments were
emoved and the culture continued to reach 80% conﬂuence. The
ells were dissociated by trypsin and EDTA in PBS. Cells were either
ultured or cryopreserved for further use.
.2. Cells characterization
.2.1. Immunocytochemistry of actin ﬁlament
To assess the myoﬁbroblastic nature of the harvested cells, pas-
ages two of hUCMCs were immunostained for -SMA (mouse
onoclonal Clone 1A4; Sigma, A2547) to clarify the presence of
ctin ﬁlaments in isolated cells. The cells were cultured on a glass
lide for 48 h. The cells were then rinsed with PBS and ﬁxed in 4%
araformaldehyde for 5 min  at 4 ◦C. The slides were then blocked
ith 10% normal goat serum for 30 min  at room temperature and
ashed with PBS. The slides were incubated with primary anti-
ody for 60 min, washed with PBS and incubated with secondary
ntibody (human anti-mouse IgG) for 60 min  at room tempera-
ure. Finally, the cells were stained with 3,3′-diaminobenzidine and
bserved by a phase contrast inverted microscope (Olympus, IX71,
okyo, Japan).Cell 47 (2015) 395–405
2.2.2. Alkaline phosphatase assay
Passage two  cells were cultured in 35 mm culture dishes until
colony formation by refreshing the medium every 72 h. Alkaline
phosphatase activity was detected using an AP Kit (Sigma–Aldrich
Chemie GmbH, Germany, Catalog No. 86-1) according to the man-
ufacture’s instruction. A red reaction product after exposure to
alkaline dye mixture conﬁrmed AP activity.
2.2.3. Osteogenic and adipogenic differentiation
For osteogenic and adipogenic differentiation of hUCM cells,
5 × 103 viable passage three cells were cultured in 35 mm cul-
ture plates for 24 h. The osteogenic medium; DMEM,  supplemented
with 10% FBS, 10 nM dexamethasone, 10 mM -glycerophosphate
and 82 g/ml ascorbic acid, was added to the culture plates for
21 days. The adipogenic medium consisted of DMEM-F12 supple-
mented with 15% equine serum and 100 nM dexamethasone was
added to the culture dishes for 14 days. The same procedure was
carried out for negative control group, except the inducing agents
were removed. To visualize osteogenic and adipogenic differentia-
tion, the induced cells were respectively exposed to Von Cossa to
detect black calcium phosphate deposits and Oil-red-O to detect
red lipid droplets in adipocytes.
2.2.4. Cell surface analysis by ﬂowcytometry
1 × 104 viable cells at passages two were harvested by
trypsinization. Suspended cell were ﬁxed by 4% paraformalde-
hyde for 15 min  and permeabilized with triton ×100 for 15 min
at 4 ◦C. After washing in PBS, the cells were incubated with 10%
goat serum in PBS at 4 ◦C for 15 min  to block non-speciﬁc binding
sites. The cells were then incubated for 1 h with FITC conjugated
human anti mouse primary antibodies; CD34, CD44, CD45 and PE
conjugated anti CD73, CD90 and CD105. At least 10,000 events
were recorded with FACS Canto ﬂow cytometer (BD Biosciences,
San Jose, CA) machine. The data were analyzed on FACS Diva soft-
ware (BD Biosciences). The cells of control group were stained with
matched isotype antibodies (FITC- and PE-conjugated mouse IgG
monoclonal isotype standards), which were conﬁrmed by positive
ﬂuorescence of the limbal samples.
2.3. Differentiation of hUCM into insulin-producing cells
For differentiation to IPCs, 3rd passage cells were cultured for
a week with basal medium containing DMEMF12 supplemented
with 10% FBS, as pre treatment stage. This was for cells expanding
and reaching conﬂuence. Then the hUCMs were induced for IPC
differentiation by a three steps protocol as follow:
Step 1: The cells were cultured in 20%, 40% and 60% NCM to
determine nestin expression ratio according to the different con-
centrations of NCM. Then the cells of each concentration were
immuno-stained for nestin.
Step 2: NCM pre-treated cells of each NCM concentration were
cultured in DMEMF12 (5 mM glucose) supplemented with 2% FBS,
10 mM nicotinamide and 1/100 ITS (Insulin-transferrin-selenium,
Gibco) for one week, and the cells’ morphology was assessed daily.
Then RT-PCR was done on cells of different concentrations of
NCM to detect the PDX1 expression. After observing higher PDX1
expression with 60% NCM concentration, the other analyses of the
cells of 2nd and 3rd steps were done with the cells, cultured in 60%
of NCM.
Step 3: The cells, cultured with 60% NCM, were cultured for 2
weeks in DMEMF12 (25 mM glucose) plus 2% FBS, 10 mM nico-
tinamide, 1/100 ITS and 20% stem cell conditioned medium (SCM)
to produce islet-like cell clusters.





























wig. 1. Human umbilical cord (A). Wharton’s jelly fragments explant culture (B). The
hape, 7 days after culture (C). The conﬂuent cells at passage one formed colony (D)
n  the colonies of hUCMs (F).
.3.1. Preparation of neuronal conditioned medium (NCM)
The brains of 7 days old male Wistar rats were removed and
ashed with PBS. The supernatant was removed and the precipitate
as immersed in 10% FBS + DMEMF12. The precipitate composed
f brain tissues was abraded 15 times to obtain single cells. The
ells were cultured in DMEMF12 supplemented with 10% FBS at
7 ◦C and 5% CO2 in the humidiﬁed air. The following day, 2 mM
raC was added and 3 days later the NCM medium was harvested
or further use. It was used to produce nestin positive cells from
UCMCs (Fu et al., 2006).
.3.2. Preparation of stem cell conditioned medium (SCM)
For the preparation of SCM medium, the hUCMs were cultured
n DMEMF12 supplemented with 2% FBS, 10 mM nicotinamide and
 mM glutamine. Three days later, the medium was removed and
sed as SCM medium.
.4. Anti nestin immuno-staining
To detect nestin expression in hUCMCs incubated with differ-
nt concentrations of NCM at step 1, we treated the slides of the
nduced cells with 10% FBS in PBS to block nonspeciﬁc binding sites
f anti nestin antibody. The slides were washed with PBS and incu-
ated for 1 h with mouse anti-human nestin antibody (Chemicon)
t 1/200 dilution, A HRP system supplied by Dako was applied for
5 min  to visualize mouse IgG (EnVision + system, HRP). The slides
ere washed 3 times with PBS at intervals. The cells were observed
nder a light microscope (Nikon TS100) to calculate the proportion
f nestin positive cells.
.5. Effect of various NCM concentrations on PDX1 expression1 × 106 passage 2 cells were cultured in 20%, 40% and 60% NCM
or 5 days. The cells were harvested to detect expression of PDX1
ith RT-PCR (see infra for method). PDX1 RNA bands were scannedigrating cells at the boundary of the Wharton’s jelly fragments with ﬁbroblastic like
ive reaction of hUCMs to SMA  antibody (E). Positive alkaline phosphatase activity
and quantiﬁed with scanning the optic densities by using ImageJ
software (NIH, USA).
2.6. Reverse transcription-PCR (RT-PCR) of PDX1 and insulin gene
To determine the effect of low and high glucose medium and the
medium with and without SCM on PDX1 and insulin gene expres-
sion, RT-PCR was carried out on harvested cells of 2nd and 3rd
steps. 1 × 106 induced hUCM cells at stage two  and three were
harvested. Total RNA was  extracted by 1 ml  Trizol (Invitrogen),
chloroform and isopropanol. RNA concentration was measured by
a spectrophotometer at 260 nm.  For elimination of DNA contam-
ination, 1–2 g of template RNA samples were exposed to 2.0 IU
DNase I (Fermentas) at 37 ◦C for 30 min  and inactivated with 2 l
25 mM EDTA at 65 ◦C for 10 min. One microgram DNase-digested
total RNA was  reverse transcribed with Meloney murine leukemia
virus (M-MuLV) reverse transcriptase enzyme in the presence of
oligo-dT primer at 42оC for 1 h. cDNA concentration was measured
by a spectrophotometer at 260 nm.  The cDNA product was ampli-
ﬁed for 30 cycles using the following primer sequences: insulin
(240 bp), forward: 5′-AGC CTT TGT GAA CCA ACA CC-3′, reverse: 5′-
GCT GGT AGA GGG AGC AGA TG-3′, PDX1 (220 bp), forward: 5′-GGA
TGA AGT CTA CCA AAG CTC ACG C-3′, reverse: 5′-CCA GAT CTT GAT
GTG TCT CTC GGT C-3′). The PCR products were fractionated with
electrophoresis by 1.5% agarose gel. Beta actin (321 bp) was used as
housekeeping gene, sense: 5′-ATGGCCACGGCTGCt CCAGC-3′, Anti
sense 5′-CAGGAGGAGCAATGATCTTGAT-3′.
2.7. Insulin immunocytochemistry
The cells of stage three, were ﬁxed for 20 min  with 4%
paraformaldehyde in 0.1 M phosphate buffer at 4 ◦C. Following
washing with PBS, they were permeabilized for 1 h with 0.5% triton
×100. After subsequent washing with PBS, the cells were treated
with 10% normal goat serum in a humidiﬁed chamber for 30 min
at room temperature to prevent nonspeciﬁc antigen–antibody
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indings. The cells were then washed with PBS and the induced
ells at 2nd and 3rd stage were incubated at 4 ◦C with 1/200 dilu-
ion of anti insulin antibody (Guinea pig polyclonal anti insulin
ntibody) followed by goat anti guinea pig secondary antibody con-
ugated with Texas red (Abcam®) for 1 h and mounted with glycerol.
he cells nuclei were visualized by 5 g/ml Hoechst 33258 (Sigma)
or 10 min. Induced cells were then observed with a ﬂuorescence
nverted microscope (Olympus IX71) equipped with a digital cam-
ra (DP71).
.8. Glucose challenge test (insulin release and C-peptide
ecretion level)
To detect whether the IPCs at stage 3, induced with 60%
CM, could response to higher glucose concentrations, the culture
edium was refreshed with DMEM (5.5 mM glucose) and 4 h later a
ample was collected and stored at −20 ◦C as control. The cells were
hen washed several times with PBS, cultured for another 4 h in high
lucose DMEM (25 mM glucose) with 0.5% BSA. A sample of culture
edium was harvested and stored at −20◦ C. The insulin and C-
eptide level was measured by enzyme-linked immuno-absorbent
ssay kit (ELISA), according to the manufacturer’s protocol. The test
as repeated three times.
.9. In vivo analyses
.9.1. Animal housing
Sixty male Wistar rats weighting 200–250 g and normal blood
lucose level were obtained from animal house of Afzalipour School
f Medicine (Kerman, Iran). They were kept under standard housing
onditions with 12 h light/dark cycle and 21–25 ◦C temperature.
hey received ad libitum access to standard laboratory rat food and
ater. Also they were supported under human care according to the
Guide for the Care and Use of Laboratory Animals”, approved by
he Research Council of Afzalipour School of Medicine.
.9.2. Diabetes induction in rats and cell transplantation
By intra-peritoneal injection of streptozotocin (STZ, 50 mg/kg)
n two consecutive days, experimental type I diabetes was induced
n Rats. The rats maintained deprived of food 12 h before STZ injec-
ion. Before injection, the animal blood sugar was  measured with
lucometer (Lifescan). Immediately after STZ injection, the rats
eceived 20% sugar solution for 8 h. Three days after STZ injection
nd every week until the end of experiments, the animal blood
ugar was measured. Animals with fasting blood sugar (FBS) of
300 mg/dl were considered as diabetic. In addition, clinical signs
ike polyurea, polypepsia and weight loss were noted as diabetes
ndicators. Diabetic animals were divided into 4 groups (n = 8). They
ere anaesthetized by intramuscular injection of 400 mg/kg chlo-
ide hydrate. In the differentiated cell treated group (Dif-hUCM),
 × 106 step three cells were slowly injected under the right kid-
ey capsule with a 22#G needle via laparotomy. In the other
roup of diabetic animals (hUCM), 2 × 106 undifferentiated cells
ere injected under the right kidney capsule. Cell treated groups
eceived 10 mg/kg/day cyclosporine to suppress probable immune
esponse. The vehicle group received the same volume of PBS and
he sham group endured laparatomy and kidney capsule incision
ithout any further manipulation.
.9.3. Blood sugar and body weight assessment
Blood samples were taken from the tail vein and the glucose was
easured by glucometer, the ﬁrst day and the day after treatment
nd each week for 8 weeks. The animals’ weight was  recorded the
rst day and weekly for 8 weeks with a digital balance.Cell 47 (2015) 395–405
2.9.4. Immunohistochemistry
Rats were euthanized by chloroform inhalation 8 weeks latter
and right kidneys were removed with a sharp scissors and ﬁxed
in 10% formalin. The parafﬁn embedded tissues were cut into 5 m
sections. The sections were incubated with primary guinea pig anti-
human insulin antibody (1:100) for 24 h at 4оC. The samples were
then washed with PBS, incubated with FITC-conjugated goat anti-
guinea pig IgG secondary antibody (1:300) for 1 h, mounted with
glycerol and examined under a ﬂuorescent microscope.
2.10. Statistical analysis
Data from different groups were analyzed by one-way ANOVA
except for the analysis of C-peptide and insulin secretion that Stu-
dent T test was applied. P value <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. In Vitro analyses
3.1.1. Isolation of hUCM cells
The isolated cells were observed at the periphery of the explants
around the day 7 of culture (Fig. 1C) and the Wharton’s jelly seg-
ments were removed at day 10 of culture. The culture reached
conﬂuence 7–8 days later. The cells were passaged and transferred
to new ﬂasks. Cells colonies appeared (Fig. 1D) 8–10 days after ﬁrst
passage. These cells had a ﬁbroblastic appearance with numer-
ous cytoplasmic extensions. Mitotic activity was evident in the
culture.
3.1.2. Alkaline phosphatase and actin detection
Immunocytochemical analysis of alpha smooth muscle actin
protein demonstrated a positive reaction to actin antibody which
conﬁrmed the myoﬁbroblastic nature of the cells (Fig. 1E). Also,
alkaline phosphatase activity was  detectable among the isolated
cells and colonies by a red product (Fig. 1F).
3.1.3. Osteogenic and adipogenic differentiation
To evaluate the differentiation capacity of the isolated cells, their
osteogenic and adipogenic potentials were assessed. The untreated
control cells neither showed positive reaction to Van Cossa stain-
ing (Fig. 2A) nor oil-red-O staining (Fig. 2B). About 14 days after
the onset of osteogenic induction, the cells demonstrated positive
reaction to Von Cossa staining by black extra cellular deposits of
calcium phosphate (Fig. 2C).
Adipogenic differentiation resulted in fat droplets in the cyto-
plasm of induced cells about 6 days after induction, the ﬁrst oil
droplets were observed in the induced cells. The oil-Red-O stain-
ing revealed the red fat droplets in the differentiated cells after 14
days (Fig. 2D). As positive control, in the section of bone, the cal-
cium deposits were visualized as red to dark spots (Fig. 2E) and the
fat vacuoles in the fat tissue section showed positive reaction to
oil-red-O staining (Fig. 2F).
3.1.4. Flow cytometry
Mesenchymal surface markers expressed in hUCMs are shown
in the diagrams (Fig. 3). Results showed that hUCM cells did not
express CD34 and CD45 while they expressed CD44, CD73, CD90
and CD105 (as mesenchymal stem cells markers). Data are the
average values obtained from three different umbilical cords.3.2. Nestin expression
At the ﬁrst stage of induction, the cells were cultured with
20%, 40% and 60% NCM and evaluated for nestin expression by
M.  Moshreﬁ et al. / Tissue and Cell 47 (2015) 395–405 399
Fig. 2. hUCMs were used as control for osteogenic (A) and adipogenic (B) differentiation. Dark purple calcium phosphate deposits formed in the extracellular matrix of








(E).  A section of fat tissue used as positive control for adipogenic differentiation. The
he  text, the reader is referred to the web version of this article.)
mmunocytochemistry. These cells exhibited a positive reaction to
estin antibody. The proportion of nestin positive cells was  17%,
1%, and 85%, in 20%, 40% and 60% NCM concentration, respectively
Fig. 4A–C). No reaction was observed in untreated cells (Fig. 4D),
hile brain slices (positive control) expressed nestin obviously
Fig. 4E).s demonstrate the fat droplets (F). (For interpretation of the references to color in
3.3. The effect of NCM concentration on PDX1 expressionAfter initial culture of hUCM cells, the propagated cells were
exposed to various concentrations of NCM then PDX1 expression
was determined by RT-PCR. The outcome of ImageJ software analy-
sis demonstrated that optical density of PDX1 expression was 0.44,
400 M. Moshreﬁ et al. / Tissue and Cell 47 (2015) 395–405
Fig. 3. Mesenchymal stem cell marker expression was detected by ﬂowcytometry in hUCMs.








tig. 4. Positive reaction to anti nestin antibody in hUCMs cultured with 20% (A)
oncentration increased. The percentage of nestin expression in 20%, 40% and 60% 
ontrol  (D) and a section of brain, was  used as positive control and the arrows show
.59 and 0.83 in 20%, 40% and 60% NCM concentrations, respec-
ively. So, further experiments were carried out in the presence of
0% NCM (Fig. 5).
.4. Differentiation of hUCM to insulin producing cellsAfter stage one (Fig. 6A), the cells were exposed to pancre-
tic inducing mediums through stages two and three. From stage
wo, some granule like structures formed and increased in the cells(B) and 60% NCM (C). The number of nestin positive cells increased when NCM
concentrations was 17%, 31%, and 85%, respectively. hUCMs were used as negative
in positive cells of brain (E).
(Fig. 6B and C). Simultaneously, the cells shape changed from spin-
dle to oval and round appearance (Fig. 6C). These cells started to
aggregate (Fig. 6D) and accumulated to become more compact
structures resembling islet like structures (Fig. 6E and F).3.5. Insulin immunocytochemistry
The cells of the stage three (cultured with 60% NCM) were
stained with anti-insulin antibody to detect insulin production
M.  Moshreﬁ et al. / Tissue and Cell 47 (2015) 395–405 401






































areas  were A: 26,469.271, B: 28,505.927, C: 29,368.756, a: 11,878.279, b: 16,869.1
as:  a/A: 0.448, b/B: 0.591, c/C: 0.837. So, the output of ImageJ analysis software 
.44,  0.59 and 0.83, respectively.
n the induced cells. Control slide of un-differentiated cells was
tained with Hoechst (Fig. 7A) and anti-insulin (Fig. 7B). These
lides demonstrated no positive reaction to anti insulin antibody
Fig. 7B and C). The treated cells were also stained with Hoechst
Fig. 7D) and anti insulin antibody (Fig. 7E). A positive reaction
o anti-insulin antibody was demonstrated in non-aggregated dif-
erentiated cells (Fig. 7E and F). Also, the accumulated cells were
tained with Hoechst (Fig. 7G) and anti insulin antibody (Fig. 7H)
nd they exhibited positive reaction to anti- insulin antibody
Fig. 7H and I).
.6. PDX1 and insulin gene expression
To detect whether the induced cells progressed toward the IPCs,
e analyzed PDX1 and insulin expression by RT-PCR. The RT-PCR
nalysis of induced cells at stages two and three demonstrated a
20 bp band for PDX1, a 240 bp band for insulin and 600 bp band
or beta actin, as housekeeper gene (Fig. 8).
.7. Estimation of insulin secretion and C-peptide release
The amount of insulin and C-peptide was in parallel with each
ther. Insulin secretion was more pronounced than C-peptide at
ow and high glucose concentrations (5.5 and 25 mmol) (Fig. 9A).
.8. Blood sugar level in diabetic rats
The STZ-induced diabetes rats were treated with 3rd stage dif-
erentiated cells and with hUCM, as control. The body weight and
lood sugar levels were evaluated as described earlier. Seven days
fter STZ injection, the blood sugar raised above the normal level
nd reached a plateau of about 400 mg/dl and remained high in
onsecutive weeks of experiments in control and sham groups. Diff-
UCM treated rats also showed a rapid increase in blood glucose at
st week but at 3rd week it fall below 300 mg/dl and after 8 weeks it
eclined below 200 mg/dl, that was signiﬁcantly lower than control
nd sham groups (P < 0.05). Undiff-hUCM treated rats also showed
 rapid rise to 420 mg/dl in blood glucose in one week but during
he succeeding weeks it decreased to 325 mg/dl. At the end of the
nal level, blood glucose was 325 and 186 in Diff-hUCM and hUCM
roups, respectively. But blood glucose level in hUCM treated rats
as not signiﬁcantly different from control and sham groups, while
n Diff-hUCM treated animals it was signiﬁcantly lower than control
nd sham (Fig. 9B * and **). 24,604.513 and the proportionate of each PDX1 gene expression to its beta actin
strated that the PDX1 expression in 20%, 40% and 60% NCM concentrations were
3.9. Body weight gain
A considerable but not signiﬁcant weight loss was  observed in
all groups, during the ﬁrst week after treatment. Weight loss con-
tinued until the 4th week in all groups without any signiﬁcant
difference. From the 4th weeks, the Diff-hUCM treated animals
started to gain weight gradually but hUCM group did not show a
considerable weight gain after the 4th week. Control and sham ani-
mals continued to weight loss toward the end of the experiments
(Fig. 9C). These gradually increase of weight in Diff group may  be
related to the time need for cells compatibility with kidney capsule
tissues.
3.10. Immunohistopathology
The STZ treated animals were euthanized with cervical disloca-
tion two mounts after cell transplantation and their kidneys were
removed, ﬁxed, sectioned and evaluated under ﬂuorescent micro-
scope and the transferred cells were detected in the treated animals
beneath the kidney capsule after labeling with anti human speciﬁc
antibody (Fig. 9D).
A graphical abstract has been presented to show the steps of the
experiments and the main outcomes.
4. Discussion
In our study, treatment of DM rats with Diff-hUCM cells resulted
in considerable decline of blood glucose one month after treatment
followed by a higher decrease in the next month. Mesenchymal
stem cells have been proposed as a suitable candidate for the treat-
ment of diabetes and elimination of its complication (Volarevic
et al., 2011). Up to now, bone marrow mesenchymal cells have been
reported as the most preferred tissue in cell therapy procedures
but due to the limited number of bone marrow mesenchymal cells,
other stem cells sources is demanding (Kassem et al., 2004). Wu
et al. (2009) reported that Wharton jelly mesenchymal cells have
more advantages than bone marrow mesenchymal cells in cell ther-
apy procedures. These cells are more primitive compared to other
kind of adult mesenchymal stem cells. It has been shown that differ-
entiation of Wharton’s jelly cells to IPCs, resulted in larger clusters,
higher PDX1 expression and more insulin and C-peptide production
(Wu  et al., 2009). These studies suggest that hUCM cells can prob-
ably serve as a suitable candidate for pancreatic tissue engineering
and cell therapy (Godfrey et al., 2012).
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Fig. 6. The expanded hUCM cells at stage one (A). The arrows show the granule like structures formed in differentiated cells of 2nd stage (B). The spindle shape of induced
cells  changed to round shape at 2nd stage. The ﬁgure shows a round cell with granule like structures in its cytoplasm which the arrows indicate them (C). The cells of 3rd
stage  are accumulating (D) to make an islet like structure (E). A fully formed islet like structure with round cells at its margin (F).
Fig. 7. Immuno ﬂorescent view of insulin antibody in cell clusters. Hoechst (A) and anti insulin staining of undifferentiated cells (B and C), used as negative control. Hoechst
(D)  and anti insulin staining (E and F) of differentiated cells. Hoechst (G) and anti insulin staining (H and I) of an aggregation of the differentiated cells which demonstrate
positive reaction to insulin antibody.



















2ig. 8. The RT-PCR of PDX1 and insulin gene in differentiated cells of 2nd and 3rd
tages.
Stem cell therapy faces some challenges. For example, the most
fﬁcient kind of cells without further complications for pancreas
egeneration has not still been introduced (Chao et al., 2008;
odfrey et al., 2012). As hUCMs have been nominated as immuno
odulator, they reduce the immune rejection probability of trans-
lanted cells. Compare to other MSCs, they exhibit unusual immune
roperties (Anzalone et al., 2011) without expressing type II HLA
Turnovcova et al., 2009). They can alleviate immune reaction
rocesses which in type I diabetes causes beta cells destruction
Anzalone et al., 2011). This fact in parallel to the replacement of
ig. 9. Diagrams show C-peptide and insulin secretion levels, evaluated by ELISA (A). Both p
esulted  in insulin and C-peptide secretions in culture medium, after 24 h. The insulin secr
lso,  the insulin and C-peptide secretion levels were propitiate to glucose concentration.
wo  weeks after cell transplantation, the glucose level in the Diff-hUCM and hUCM trea
ham and vehicle groups. Fall in glucose concentration continued toward the end of expe
owever, never it did not returned to normal values (B). Diagram shows a non-signiﬁcan
igniﬁcantly at the end of experiment in Diff-hUCM group compared with hUCM group (C)
 months after cells transplantation (D).Cell 47 (2015) 395–405 403
the destructed beta cells, are the probable mechanisms by which
hUCM cells may  control diabetes signs.
In our study, both differentiated and un-differentiated cells
altered the blood glucose level but in differentiated cells group,
it reduced blood glucose to a considerable and signiﬁcant level
compared with control animals.
Nicotinamid is an endocrine differentiation factor and glucose
is need for secretion of insulin, so from stage two, we applied
mediums, containing glucose and nicotinamid. Nestin is a precursor
marker for islet cells differentiation. Stage one was just an interme-
diate step between pancreatic and neural differentiation that are
common in nestin expression (Horwitz et al., 2005). In our study
we ﬁrst evaluated the effect of different concentrations of NCM, as
an inducer of nestin, on nestin and PDX1 expression. The results
showed that higher NCM concentration could lead to more nestin
and PDX1 expression.
Expression of nestin in stage one conﬁrmed successful passage
of hUCMs through the intermediate stage of neuronal and pancre-
atic differentiation. Inhibition of nestin expression has led to the
decrease of pancreatic transcription factors in ESCs and pancreatic
derived precursor cells (Lumelsky et al., 2001). Exposure of hUCMs
to higher concentration of NCM resulted in higher PDX1 expression,
as a marker of IPCs.
Glucose and amino acids (De Gasparo et al., 1978), are neces-
sary for pancreatic differentiation, therefore at stage two and three
we cultured hUCMs in a medium containing higher glucose con-
centration, to stimulate their differentiation. In addition, insulin
is necessary for glucose absorption (Deane et al., 2011), so we
hysiological glucose concentration (5.5 mM)  and induced hyperglycaemia (25 mM)
etion levels were higher than those of C-peptide in either of glucose concentrations.
 Blood glucose increased until 7–9 days of the induction of diabetes in the animals.
ted animals started to decrease signiﬁcantly in Diff-hUCM group compared with
riment at a ﬁnal level of 325 and 186 in Diff-hUCM and hUCM groups, respectively.
t weight lose after cell transplantation in Diff-hUCM and hUCM groups. It changed
. Presence of transplanted cells under the kidney capsule at the end of experiments,
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sed ITS, as an insulin containing mixture at stage two and three.
ddition of ITS in culture medium enabled us to reduce FBS con-
entration as low as 2%. Higher glucose concentrations have been
hown to inhibit IPC differentiation. It has been shown that when
uman neuronal progenitor cells, which produce nestin, are cul-
ured in a high glucose medium, they start to aggregate and produce
ell cluster (Hori et al., 2005). It should be noted that, due to the
esistance to insulin sensitivity, exposure to glucose at stage two
nd three should not last for prolonged time. Similar to in vitro beta
ells behavior, the IPCs initiate insulin secretion when glucose level
levates in the medium so that the induced cells started to secret
nsulin after glucose challenge test (Chao et al., 2008). We  detected
DX1 expression at stage two and three, which show that the cells
ere passing through an intermediate stage toward pancreatic dif-
erentiation. PDX1 is expressed in the pancreas progenitor cells,
hich have the potential to differentiate into all kinds of pancreas
ells (Chen et al., 2009). The expression of PDX1 discriminate these
ells from the other pancreatic endocrine cell (Wang et al., 2001).
lthough, the expression of PDX1 lonely, is not sufﬁcient for induc-
ng insulin mRNA expression, its co-expression with other genes
ike NKX2.2 is necessary for insulin gene expression (Zhou et al.,
013). PDX1 activates glut2 which is essential for sensitivity to
nvironmental glucose level (Gradwohl et al., 2000). It was also
eported that PDX1 expression level is related to pancreas genes
xpression pattern and IPCs differentiation.
We assessed insulin and PDX1 at stage three because we
xpected insulin production and secretion at stage three (Gallo
t al., 2007). Nicotinamid is essential for endocrine differentiation
Cho et al., 2008), especially for increasing the beta cells mass in
uman fetal pancreatic cells (Otonkoski et al., 1993; Cho et al.,
008). Also, it protects beta cells from glucose resistance, produced
n long-lasting exposure to large amounts of glucose (Freeman et al.,
006). We used nicotinamide for stage two and three to promote
PC differentiation.
Animal blood sugar, as a critical complication in diabetes, also
ecreased considerably one month after transplantation of induced
UCM cells. This delay might be due to the time needed for cells
ompatibility with host body. However, still the long term activity
f in vitro induced hUCMs as well as their physiologic roles in “in
ivo” conditions requires to be investigated.
C-peptide is produced via converting pro insulin to insulin and
ts serum level is associated with blood insulin level. The in vivo
mounts of insulin and C-peptide are balanced to blood glucose
evel (Kemmler et al., 1971).
One of the challenges of cell transplantation is the engrafted
ite. It should be accessible and sustain the microenvironment of
ransplanted cells for oxygen, nutrient supplies and long term sur-
ival of the cells. Also it should be either efﬁcient for cell survival
r for cell function. Portal vein, liver (Pepper et al., 2013; Carlsson
t al., 2001), spleen (Gray, 1990), omentum, pancreas, muscle, gas-
ric sub mucosa, subcutaneous, genitourinary tract, anterior eye
hamber, thymus and testis are the suggested sites for animal islet
ransplantation (Cantarelli and Piemonti, 2011; Rajab, 2010). Renal
ub capsular space can provide a better condition for transplanted
slet cells (Mellgren et al., 1986; Si et al., 2001; Hawthorne et al.,
011) and it is the most widely used site in rodents (Pepper et al.,
013). Also, in human it was reported that kidney, liver, muscle,
nd omentum are respectively the best sites for islet transplan-
ation (Kim et al., 2010). Transplantation of cells into the liver is
echnically challengeable as the liver is a fragile tissue and any
anipulation in the parenchyma of liver may  result in sever hem-
rrhage. In the present study we used renal sub capsular space for
ransplantation of the differentiated cells as an ideal site for cell
urvival and function. Via sub capsular site we could show long
erm survival of hUCMs and insulin secretion in diabetic rats. All
ogether, we may  conclude that hUCMs are capable of successfulCell 47 (2015) 395–405
differentiating into insulin producing cells. Transplantation of these
cells, as a good candidate for beta cell regeneration, into rat model
of diabetes would control weight loss and blood sugar considerably.
However, achieving higher insulin production in differentiated
cells, longer survival of cell treated animals and improved cell ther-
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